Tecartus denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for tecartus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Tecartus as Experimental or Investigational — and How to Appeal

Tecartus (brexucabtagene autoleucel) is FDA-approved for two indications: relapsed or refractory mantle cell lymphoma (MCL) after prior therapy including a BTK inhibitor, and adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). A BCBS denial characterizing Tecartus as "experimental or investigational" for either of these FDA-approved indications is legally and clinically unsustainable, and should be aggressively appealed.

## Why This Denial Is Appealable

FDA approval of a drug or biologic is the regulatory determination that safety and efficacy have been established for a specific indication. Once the FDA has approved a product, characterizing it as "experimental" for that approved indication is internally contradictory. BCBS's own medical policies and the federal appeals process both recognize that FDA-approved treatments for approved indications may not be denied as experimental. CMS coverage policy under NCD 110.24 explicitly covers FDA-approved CAR-T cell therapies. If BCBS is applying an outdated medical policy that predates one of Tecartus's FDA approvals — or misreading the indication — the denial reflects a policy administration error.

If BCBS is denying Tecartus for an off-label use (i.e., a diagnosis not covered by either FDA-approved indication), that is a distinct issue, but MCL and B-ALL are both on-label indications. Confirm the patient's confirmed diagnosis aligns with the approved indication.

## Federal Appeal Framework

• Internal appeal: File within 180 days, citing FDA approval date and indication in the appeal letter itself. BCBS must respond within 30 days (pre-service) or 60 days (post-service).
• Expedited appeal (72 hours): CAR-T timing is clinically urgent for aggressive lymphoma and B-ALL; request expedited review and document clinical urgency in the appeal.
• External review (ACA §2719 / ERISA §503): Request external review immediately after adverse internal decision. An independent hematologist-oncologist reviewer applies current clinical standards. The ~4-month external-review window closes quickly; do not wait.
• State insurance department complaint: If BCBS is a state-regulated plan and denies an FDA-approved treatment as experimental, a concurrent complaint to the state insurance commissioner is appropriate and often accelerates resolution.

## Documentation to Gather

1. FDA approval documentation: Reference to the specific FDA approval date and indication for Tecartus applicable to the patient's diagnosis (available in the FDA-approved prescribing information and the FDA Hematology/Oncology approvals database). 2. Diagnosis confirmation: Biopsy with pathology (MCL: cyclin D1 positivity, t(11;14); B-ALL: flow cytometry, cytogenetics, FISH) confirming the on-label diagnosis. 3. Prior-therapy history: Documentation that prior-therapy requirements in the FDA-approved indication are met (prior BTK inhibitor exposure for MCL; relapsed/refractory status for B-ALL). 4. Prescriber medical-necessity letter: The treating hematologist-oncologist confirming FDA-approved indication, NCCN guideline alignment, and clinical urgency. 5. REMS/ATC documentation: Confirmation of FACT-accredited REMS-certified authorized treatment center.

## Criteria-Mapping Structure

Obtain BCBS's current CAR-T medical policy and Tecartus's FDA-approved prescribing label. Directly confront the experimental-denial basis:

| Denial Basis | Appeal Response | |---|---| | "Experimental/investigational" designation | FDA approval date + indication statement from label | | Policy version that predates approval | Request BCBS to apply current policy | | Confirmed on-label diagnosis | Pathology report | | Prior-therapy requirement met | Treatment history with dates and regimens | | NCCN listing as recommended regimen | Treating oncologist letter citing applicable NCCN guideline |